Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 4/2021

01-08-2021 | Computed Tomography | Original Article

Does the Incremental Value of 123I-Metaiodobenzylguanidine SPECT/CT over Planar Imaging Justify the Increase in Radiation Exposure?

Authors: Dorra Ben-Sellem, Naima Ben-Rejeb

Published in: Nuclear Medicine and Molecular Imaging | Issue 4/2021

Login to get access

Abstract

Purpose

Planar scintigraphy with 123I-radiolabeled metaiodobenzylguanidine (123I-mIBG) is an important imaging modality to evaluate neuroblastoma. In recent years, Single Photon Emission Computed Tomography combined with Computed Tomography (SPECT/CT) has revolutionized nuclear medicine. Nevertheless, the addition of the CT has increased the patients' irradiation. We aimed to evaluate the incremental benefits of 123I-mIBG SPECT/CT over conventional planar imaging and to estimate the relative increase of radiation dose.

Methods

We retrospectively evaluated the added value of 56 SPECT/CT performed in 40 children in terms of better characterization of the lesion and its locoregional extension, better lymph node staging, detection of new lesions, and elimination of false positives by a paired comparison between the planar images and the SPECT/CT ones. Then, we calculated the percentage contribution of the additional radiation of the CT in this hybrid imagery.

Results

In 88% (49 out of 56) of the examinations, SPECT/CT provided additional information, which was crucial in 20% of the cases. It allowed a better characterization of the lesion and its locoregional extension in 44 cases, a better lymph node staging in 28 cases, the detection of 33 new lesions, and the elimination of 9 false positives. The CT effective dose was significantly lower than the SPECT one. The average additional radiation exposure due to CT was 12% (4–23%).

Conclusion

123I-mIBG SPECT/CT has an undeniable added value that improves planar imaging interpretation and impacts patient management. These potential benefits would justify the low additional radiation induced by the CT.
Literature
1.
Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009;23:125–43.CrossRef
2.
Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–97.CrossRef
3.
Lonergan GF, Schwab CM, Suarez ES, Carlson CL. From the archives of the AFIP neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologicpathologic correlation. Radiographics. 2002;29:911–34.CrossRef
4.
Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging. 2005;5:116–27.CrossRef
5.
Fukuoka M, Junichi T, Takafumi M, Seigo K. Comparison of diagnostic value of 123I- mIBG and high-dose 131I-mIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nuc Med. 2011;36:1–7.CrossRef
6.
DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21:181–9.CrossRef
7.
Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–34.CrossRef
8.
Balwierz W, Wieczorek A, Klekawka T, Garus K, Bolek-Marzec K, Perek D, et al. Treatment results of children with neuroblastoma:report of Polish Pediatric Solid Tumor Group. Przegl Lek. 2010;67:387–92.PubMed
9.
Perwein T, Lackner H, Sovinz P, Benesch M, Schmidt S, Schwinger W, et al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr Blood Cancer. 2011;57:629–35.CrossRef
10.
Boubaker A, Bischof DA. Nuclear medicine procedures and neuroblastoma in childhood Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med. 2003;47:31–40.PubMed
11.
Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the international neuroblastome risk group project. Radiology. 2011;261:243–57.CrossRef
12.
Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffoli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46.CrossRef
13.
Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, et al. 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011;38:1648–58.CrossRef
14.
Jaques S, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and miodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 1987;47:3920–8.PubMed
15.
Gasnier B, Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP. Uptake of metaiodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol. 1986;29:275–80.PubMed
16.
Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24:65–86.CrossRef
17.
Vik TA, Puger T, Kadota R, Castel V, Tulchinsky M, Farto JCA, et al. 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicentertrial. Pediatr Blood Cancer. 2009;52:784–90.CrossRef
18.
Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med. 1994;35:1753–7.PubMed
19.
Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole- body PET/CT with 11C-metahydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635–42.PubMed
20.
Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. Am J Roentgenol. 2008;190:1085–90.CrossRef
21.
Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–24.CrossRef
22.
Montes C, Tamayo P, Hernandez J, Gomez-Caminero F, Garcia S, Martin C, et al. Estimation of the total effective dose from low-dose CT scans and radiopharmaceutical administrations delivered to patients undergoing SPECT/CT explorations. Ann Nucl Med. 2013;27:610–7.CrossRef
23.
Valentin J. Radiation dose to patients from radiopharmaceuticals:(addendum 2 to ICRP publication 53) ICRP publication 80 approved by the commission in september 1997. Ann ICRP. 1998;28:1.CrossRef
24.
Jessen KA, Panzer WSP. European guidelines on quality criteria for computed tomography. brussels, belgium: European commission. journal = EUR 16262. 2000.
25.
Meyer-Rochow GY, Schembri GP, Benn DE, SywakMS, Delbridge LW, Robinson BG, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography(MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2010;17:392–400.
26.
Nadel HR. SPECT/CT in pediatric patient management. Eur J Nucl Med Mol Imaging. 2014;41:104–14.CrossRef
27.
Liu B, Servaes S, Zhuang H. SPECT/CT mIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma. Clin Nucl Med. 2018;43:232–8.CrossRef
28.
Theerakulpisut D, Raruenrom Y, Wongsurawat N, Somboonporn C. Value of SPECT/CT in diagnostic 131I-mIBG scintigraphy in patients with neuroblastoma. Nucl Med Mol Imaging. 2018;52:350–8.CrossRef
29.
Shahrokhi P, Emami-Ardekani A, Harsini S, Eftekhari M, Fard-Esfahani A, Fallahi B, et al. 68Ga-DOTATATE PET/CT compared with 131I-MIBG SPECT/CT in the evaluation of neural crest tumors. Asia Ocean J Nucl Med Biol. 2020;8:8–17.PubMedPubMedCentral
30.
Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36:258–78.CrossRef
31.
Rottenburger C, Juettner E, Harttrampf AC, Hentschel M, Kontny U, Roessler J. False- positive radio-iodinated metaiodobenzylguanidine (123I-MIBG) accumulation in a mast cell infiltrated infantile haemangioma. Br J Radiol. 2010;83:e168–71.CrossRef
32.
Frappaz D, Giammarile F, Thiesse P, Ranchere-Vince D, Louis D, Guilbaud L, et al. False positive MIBG scan. Med Pediatr Oncol. 1997;29:589–92.CrossRef
33.
Schindler T, Yu C, Rossleigh M, Pereira J, Cohn R. False positive MIBG uptake in pneumonia in a patient with stage IV neuroblastoma. Clin Nucl Med. 2010;35:743–5.CrossRef
34.
Acharya J, Chang PT, Gerard P. Abnormal MIBG uptake in a neuroblastoma patient with right upper lobe atelectasis. Pediatr Radiol. 2012;42:1259–62.CrossRef
35.
Jacobs A, Lenoir P, Delree M, Ramet J, Piepsz A. Unusual Tc-99m MDP and I-123 MIBG images in focal pyelonephritis. Clin Nucl Med. 1990;15:821–4.CrossRef
36.
Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med. 1994;35:803–10.PubMed
37.
Piccardo A, Morana G, Puntoni M, Campora S, Sorrentino S, Zucchetta P, et al. Diagnosis, treatment response, and prognosis: the role of 18F-DOPA PET/CT in children affected by neuroblastoma in comparison with 123I-mIBG scan: the first prospective study. J Nucl Med. 2020;61:367–74.CrossRef
38.
Law M, Ma WH, Leung R, Li S, Wong KK, Ho WY, et al. Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a phantom study with SPECT/CT and ICRP-103 recommendations. Eur J Radiol. 2012;81:e717–20.CrossRef
39.
Larkin AM, Serulle Y, Wagner S, Noz ME, Friedman K. Quantifying the increase in radiation exposure associated with SPECT/CT compared to SPECT alone for routine nuclear medicine examinations. Int J Mol Imaging. 2011;2011:897202–6.CrossRef
40.
Sharma P, Sharma S, Ballal S, Chandrasekhar B, Arun M, Rakesh K. SPECT/CT in routine clinical practice: increase in patient radiation dose compared with SPECT alone. Nucl Med Commun. 2012;33:926–32.CrossRef
41.
Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT. Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. BMC Med imaging. 2016;16:41–51.CrossRef
42.
Khamwan K, Krisanachinda A, Pasawang P. The determination of patient dose from 18F-FDG PET/CT examination. Radiat Prot Dosimetry. 2010;141:50–5.CrossRef
43.
Paiva F G, do Carmo Santana P, Mourao A P. Evaluation of patient effective dose in a PET/CT test. Appl Radiat Isot. 2019;145:137–41.
Metadata
Title
Does the Incremental Value of 123I-Metaiodobenzylguanidine SPECT/CT over Planar Imaging Justify the Increase in Radiation Exposure?
Authors
Dorra Ben-Sellem
Naima Ben-Rejeb
Publication date
01-08-2021
Publisher
Springer Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 4/2021
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-021-00707-5

Other articles of this Issue 4/2021

Nuclear Medicine and Molecular Imaging 4/2021 Go to the issue

Interesting image

18F-FDG PET/CT Evaluation of Thymomas: a Pictorial Review

Original Article

The Role of Tc-99 m-MIBI Scan in the Assessment of the Cystic Thyroid Nodule

Review

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

Interesting image

Incidental Detection of Ischemic Myocardium on 68 Ga-FAPI PET/CT

Interesting image

Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68 Ga-PSMA PET/CT vs mpMRI

Editorial

Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements